Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National Institute for Health and Care Research (NIHR) at Southampton Clinical Research Facility.

Stablepharma’s pioneering science has progressed into the clinical trial stage thanks to funding from shareholders and the UK Government, including Innovate UK and the NIHR. The first participant was dosed in the trial on the 15^th April 2025 and is expected to be completed in Q3 2025.

Stablepharma’s next-generation technology platform StablevaX™ reformulates existing and new vaccines and biologicals into thermostable products that do not require cold storage such as refrigeration or freezing, thus eliminating the need for cold chain.

This award-winning innovation tackles major global issues which include the distribution, storage, wastage, and CO2 emissions linked to the transportation of temperature-sensitive products. The World Health Organization reports that over 50% of vaccines are wasted each year due to cold chain failures, highlighting the significant impact StablevaX™ will have in improving vaccine access and reducing waste worldwide.